Monte Rosa Therapeutics, Inc. (GLUE) Income Statement
GLUE 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsGLUE revenue and net income
Where GLUE's revenue goes
2025Each bar shows an amount and its share of revenue. GLUE kept −31.2% of revenue as net income.
GLUE profit margins
GLUE growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +63.5% | — | — | — |
| Gross profit | +70.8% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
GLUE quarterly EPS vs estimates
Monte Rosa Therapeutics beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.10).
GLUE income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $123.7M | $75.6M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $8.4M | $8.1M | $6.2M | $8.6M | $2.1M | $537,000 | $72,000 |
| Gross profit | $115.3M | $67.5M | −$6.2M | −$8.6M | −$2.1M | −$537,000 | −$72,000 |
| Research & development | $141.5M | $121.6M | $105.0M | $85.1M | $57.2M | $23.5M | $7.3M |
| Sales, general & admin | $36.4M | $35.2M | $32.0M | $27.3M | $15.7M | $4.0M | $644,000 |
| Total operating expenses | $169.5M | $148.6M | $137.1M | $112.4M | $72.9M | $27.5M | $8.0M |
| Operating income | −$54.2M | −$81.1M | −$143.3M | −$112.4M | −$72.9M | −$28.0M | −$8.0M |
| Interest income | $12.9M | $10.6M | $9.0M | $3.8M | $46,000 | $9,000 | — |
| Interest expense | — | — | — | $3.8M | $1.1M | $9,000 | $1,000 |
| Income before taxes | −$39.7M | −$70.1M | −$135.0M | −$108.5M | −$74.0M | −$35.9M | −$7.7M |
| Income taxes | −$1.1M | $2.6M | $338,000 | −$3.9M | −$2.0M | $189,000 | $277,000 |
| Net income | −$38.6M | −$72.7M | −$135.4M | −$108.5M | −$74.0M | −$35.9M | −$8.0M |
| EBITDA | −$31.4M | −$62.0M | −$128.8M | −$101.0M | −$71.8M | −$27.5M | −$7.7M |
| EPS (diluted) | −$0.46 | −$1.61 | −$2.64 | −$2.29 | −$8.05 | −$7.18 | −$3.04 |
| Gross margin | 93.2% | 89.3% | — | — | — | — | — |
| Operating margin | −43.8% | −107.3% | — | — | — | — | — |
| Net margin | −31.2% | −96.1% | — | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.0M | $4.2M | $2.8M | $12.8M | $23.2M | $84.9M | $60.6M | $9.2M | $4.7M | $1.1M | $8.8M | $0 |
| Cost of revenue | $0 | $2.0M | $2.1M | $2.1M | $2.1M | $0 | $2.1M | $2.1M | $2.1M | $1.9M | $1.8M | $1.8M |
| Gross profit | $9.0M | $2.2M | $2.8M | $12.8M | $23.2M | $84.9M | $60.6M | $9.2M | $2.6M | −$833,000 | −$1.8M | −$1.8M |
| Research & development | $48.0M | $44.1M | $42.0M | $36.7M | $30.7M | $32.2M | $38.9M | $27.6M | $26.0M | $25.1M | $27.1M | $28.3M |
| Sales, general & admin | $10.1M | $10.2M | $10.5M | $9.1M | $8.1M | $8.7M | $8.8M | $8.1M | $9.3M | $9.0M | $7.7M | $8.7M |
| Total operating expenses | $58.1M | $52.2M | $52.5M | $45.7M | $38.7M | $40.9M | $47.6M | $35.7M | $35.3M | $34.1M | $34.9M | $37.0M |
| Operating income | −$49.1M | −$50.0M | −$49.7M | −$33.0M | −$15.6M | $44.0M | $13.0M | −$26.5M | −$32.6M | −$34.9M | −$34.9M | −$37.0M |
| Interest income | $5.9M | $5.6M | $3.7M | $2.7M | $3.1M | $3.4M | $2.6M | $2.9M | $2.6M | $2.4M | $2.4M | $2.2M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $935,000 | — |
| Income before taxes | −$43.2M | −$44.5M | −$46.1M | −$30.3M | −$11.1M | $47.7M | $15.6M | −$23.8M | −$30.1M | −$31.9M | −$33.3M | −$34.7M |
| Income taxes | $208,000 | $52,000 | $59,000 | −$3.2M | $1.2M | $822,000 | $2.2M | $71,000 | $252,000 | $83,000 | −$22,000 | $170,000 |
| Net income | −$43.4M | −$44.5M | −$46.1M | −$27.1M | −$12.3M | $46.9M | $13.4M | −$23.9M | −$30.3M | −$32.0M | −$33.3M | −$34.9M |
| EBITDA | −$41.3M | −$42.4M | −$44.0M | −$28.2M | −$9.0M | $49.8M | $17.7M | −$21.7M | −$28.0M | −$30.0M | −$31.4M | −$35.1M |
| EPS (diluted) | −$0.43 | −$0.45 | −$0.55 | −$0.33 | −$0.15 | $0.57 | −$0.36 | −$0.29 | −$0.43 | −$0.53 | −$0.58 | −$0.70 |
| Gross margin | 100.0% | 51.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 56.1% | −78.3% | −21.1% | — |
| Operating margin | −547.8% | −1,188.5% | −1,787.7% | −258.3% | −67.1% | 51.9% | 21.4% | −287.8% | −695.3% | −3,284.5% | −398.3% | — |
| Net margin | −483.9% | −1,057.1% | −1,658.9% | −212.1% | −53.0% | 55.2% | 22.2% | −258.9% | −645.6% | −3,004.5% | −379.9% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in GLUE's financial statements (latest annual report filed March 17, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
GLUE financial results
In fiscal year 2025 (ended December 31, 2025), Monte Rosa Therapeutics reported revenue of $123.7 million, up 63.5% from the year before. It had a net loss of $38.6 million, a net profit margin of −31.2%. Diluted earnings per share came to −$0.46.
See the GLUE stock overview for the latest quote and news, or the GLUE chart for price history and technical indicators.
GLUE income statement FAQ
What is Monte Rosa Therapeutics's annual revenue?
Monte Rosa Therapeutics reported total revenue of $123.7 million for fiscal year 2025, which ended on December 31, 2025. That was up 63.5% from $75.6 million the previous year.
Is Monte Rosa Therapeutics profitable?
No. Monte Rosa Therapeutics reported a net loss of $38.6 million in fiscal 2025, a net profit margin of −31.2%; its operating margin was −43.8%.
What is Monte Rosa Therapeutics's gross margin?
Monte Rosa Therapeutics's gross margin was 93.2% in fiscal 2025: for every $100 of revenue, Monte Rosa Therapeutics kept $93 after the direct cost of its products and services.
How much does Monte Rosa Therapeutics spend on research and development?
Monte Rosa Therapeutics spent $141.5 million on research and development in fiscal 2025, 114.4% of revenue.
What are Monte Rosa Therapeutics's earnings per share?
Monte Rosa Therapeutics earned $-0.46 per diluted share in fiscal 2025, compared with $-1.61 a year earlier.
When will Monte Rosa Therapeutics report its next earnings?
Monte Rosa Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens.
When does Monte Rosa Therapeutics's fiscal year end?
Monte Rosa Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 17, 2026.